Key facts
- Eclipsebio’s last known valuation is $39.9M (Nov 2025).
- It has raised $23.9M; the latest was Later Stage VC ($4.9M) in Nov 2025.
- Notable investors include National Institutes of Health, University of California, Alexandria Venture Investments, Phoenix Venture Partners, iGlobe Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Eclipsebio
- ·The full record, as it builds
Funding rounds
No funding rounds for Eclipsebio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eclipsebio
Developer of cell-free genomics technologies designed to provide specialized genomics-based products and services. The company's technology focuses on increasing crosslinking and immunoprecipitation and assists in identifying ribonucleic acid binding protein targets, enabling scientists and academic customers to accelerate research and develop new and effective drugs to cure a wide range of human diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 40
- Website
- eclipsebio.com/
- Ownership
- Privately Held (backing)
Eclipsebio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eclipsebio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eclipsebio in its N-PORT filings yet. We sweep new filings monthly.